Table III. Stratified relative risk of non-Hodgkin lymphoma (NHL) after first primary solid cancer according to initial radiotherapy treatment by latency.
| Radiotherapy | No Radiotherapy | |||||
|---|---|---|---|---|---|---|
|
|
||||||
| First Primary Cancer | Obs | SIR | Obs | SIR | RR* and 95% CI | Ptrend |
| All solid cancers | ||||||
| 1-4.9 years | 826 | 1.08 | 1,741 | 1.05 | 1.09 (1.00-1.20) | 0.172 |
| 5-9.9 years | 593 | 1.12 | 1,159 | 0.93 | 1.23 (1.11-1.36) | |
| 10 + years | 323 | 1.01 | 948 | 0.93 | 1.08 (0.95-1.23) | |
| All standard radiotherapy treated solid cancers† | ||||||
| 1-4.9 years | 699 | 0.99 | 880 | 0.87 | 1.16 (1.05-1.28) | 0.097 |
| 5-9.9 years | 544 | 1.08 | 707 | 0.89 | 1.22 (1.09-1.37) | |
| 10 + years | 302 | 1.02 | 604 | 0.95 | 1.03 (0.89-1.19) | |
| Oral cavity & pharynx | ||||||
| 1-4.9 years | 33 | 1.17 | 45 | 1.47 | 0.52 (0.31-0.87) | 0.306 |
| 5-9.9 years | 23 | 1.30 | 23 | 0.95 | 1.41 (0.68-2.93) | |
| 10 + years | 17 | 1.32 | 24 | 1.04 | 1.32 (0.65-2.70) | |
| Larynx | ||||||
| 1-4.9 years | 30 | 1.25 | 10 | 1.47 | 0.86 (0.42-1.76) | 0.166 |
| 5-9.9 years | 20 | 1.09 | 3 | 0.52 | 2.08 (0.62-7.02) | |
| 10 + years | 9 | 0.59 | 10 | 1.67 | 0.39 (0.15-1.02) | |
| Thyroid | ||||||
| 1-4.9 years | 12 | 1.00 | 16 | 1.06 | 0.90 (0.42-1.95) | 0.350 |
| 5-9.9 years | 18 | 1.76 | 15 | 1.04 | 1.44 (0.70-2.98) | |
| 10 + years | 15 | 1.42 | 16 | 0.74 | 1.62 (0.77-3.42) | |
| Lung & bronchus (NSC) | ||||||
| 1-4.9 years | 31 | 0.85 | 77 | 0.98 | 1.20 (0.75-1.93) | 0.003 |
| 5-9.9 years | 18 | 1.59 | 38 | 0.86 | 1.94 (1.00-3.75) | |
| 10 + years | 13 | 2.43 | 20 | 0.69 | 2.23 (0.94-5.29) | |
| Female breast | ||||||
| 1-4.9 years | 13 0 | 0.73 | 193 | 0.80 | 0.91 (0.73-1.15) | 0.002 |
| 5-9.9 years | 128 | 0.92 | 179 | 0.86 | 1.05 (0.83-1.32) | |
| 10 + years | 97 | 1.00 | 214 | 1.00 | 1.01 (0.79-1.28) | |
| Cervix uteri | ||||||
| 1-4.9 years | 5 | 0.61 | 10 | 1.55 | 0.30 (0.07-1.27) | 0.137 |
| 5-9.9 years | 12 | 1.77 | 7 | 0.92 | 1.88 (0.64-5.54) | |
| 10 + years | 13 | 1.49 | 16 | 1.28 | 1.17 (0.51-2.70) | |
| Endometrium | ||||||
| 1-4.9 years | 37 | 1.17 | 51 | 0.83 | 1.43 (0.92-2.22) | 0.207 |
| 5-9.9 years | 31 | 1.08 | 43 | 0.75 | 1.38 (0.85-2.24) | |
| 10 + years | 25 | 0.78 | 50 | 0.80 | 0.99 (0.60-1.62) | |
| Prostate | ||||||
| 1-4.9 years | 386 | 1.10 | 42 4 | 0.84 | 1.30 (1.13-1.50) | 0.017 |
| 5-9.9 years | 258 | 1.06 | 348 | 0.91 | 1.19 (1.01-1.41) | |
| 10 + years | 84 | 0.92 | 219 | 1.02 | 0.95 (0.73-1.23) | |
| Testis | ||||||
| 1-4.9 years | 4 | 0.97 | <3 | 0.56 | 1.07 (0.20-5.88) | >0.50 |
| 5-9.9 years | 7 | 1.44 | 5 | 1.19 | 1.03 (0.28-3.75) | |
| 10 + years | 11 | 1.30 | 3 | 0.42 | 2.89 (0.71-11.71) | |
| Rectum & rectosigmoid junction | ||||||
| 1-4.9 years | 31 | 0.95 | 52 | 0.78 | 1.50 (0.84-2.68) | >0.50 |
| 5-9.9 years | 29 | 1.4 | 46 | 0.95 | 1.77 (0.96-3.27) | |
| 10 + years | 18 | 1.22 | 32 | 0.76 | 0.60 (0.27-1.32) | |
Abbreviations: NSC, non-small cell; Obs, observed; SIR, stan dardized incidence ratio; RR, re lative risk; CI, confidence interval
Exact cell counts with <3 patients are suppressed to protect patient confidentiality.
*
Poisson regression modeling used to estimate RR of NHL comparing radiotherapy treatment groups for first primary cancer stratified by sex, age, stage, and chemotherapy.
†
Includes oral cavity & pharynx, rectosigmoid junction & rectum, larynx, lung & bronchus (NSC), female breast, cervix uteri, endometrial, prostate, testis, and thyroid cancers.